TY - JOUR
T1 - Isoflavone(Phytogen) in the Treatment of Male Climacterics and Prostatism
AU - Liu, Ming Che
AU - Chiang, Han-Sun
AU - Chen, Kuan-Chou
AU - Hsieh, K.J.
PY - 2004
Y1 - 2004
N2 - Background and purpose: To elucidate the effect of isoflavone on male climacterics and
prostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25
males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)
was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.
Periodic examinations were made of the prostate size, PSA (prostate specific antigen), and
uroflow, as well as a follow up questionnaires with subjective screening of the voiding
function, sexual function, and male climacteric symptoms were given. Results: Neither the
prostate size nor serum PSA level of any patient were altered. For patients with
hypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,
n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month
(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37
ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2
months of isoflavone treatment (with an increase in the average peak flow rate of from
6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, general
weakness, and skin atrophy were found to have diminished by scoring in the group of
diseased patients. As a natural product, isoflavone was quite acceptable to these middle
aged to elderly patients, and no adverse effects were recorded. Conclusion: Although
neither all of the patients nor all of the symptoms were responsive to 2 months of treatment
with this medication in our series, isoflavone did, however, truly benefit some patients with
climacteric symptoms and/or prostatism and may be an alternative therapy for aging males.
AB - Background and purpose: To elucidate the effect of isoflavone on male climacterics and
prostatism. Methods: We conducted an open labeled clinical study of isoflavone on 25
males with climacteric symptoms and/or prostatism, in which 6 g of isoflavone (Phytogen)
was given daily to 25 men aged from 48 to 78 (average, 67.2) years old for 2 months.
Periodic examinations were made of the prostate size, PSA (prostate specific antigen), and
uroflow, as well as a follow up questionnaires with subjective screening of the voiding
function, sexual function, and male climacteric symptoms were given. Results: Neither the
prostate size nor serum PSA level of any patient were altered. For patients with
hypogonadism at the baseline (with an average serum testosterone level of 0.74 ng/ml,
n=8), isoflavone was shown to have resolved the testosterone deficiency after 1 month
(average testosterone level of 3.04 ng/ml) and 2 months (average testosterone level of 3.37
ng/ml) of treatment. The peak flow rate of the urine was also notably improved after 2
months of isoflavone treatment (with an increase in the average peak flow rate of from
6.17 to 12 ml/s). Some of the male climacteric symptoms such as fatigue, general
weakness, and skin atrophy were found to have diminished by scoring in the group of
diseased patients. As a natural product, isoflavone was quite acceptable to these middle
aged to elderly patients, and no adverse effects were recorded. Conclusion: Although
neither all of the patients nor all of the symptoms were responsive to 2 months of treatment
with this medication in our series, isoflavone did, however, truly benefit some patients with
climacteric symptoms and/or prostatism and may be an alternative therapy for aging males.
KW - isoflavone
KW - climacterics symptoms
KW - prostatism
KW - aging male
KW - 男性更年期
KW - 攝護腺肥大症狀
KW - 男性老化
M3 - Article
SP - 249
EP - 256
JO - Fu-Jen Journal of Medicine
JF - Fu-Jen Journal of Medicine
ER -